S63845: Selective MCL1 Inhibitor for Apoptosis Research

Executive Summary: S63845 is a potent and selective MCL1 inhibitor developed for scientific research use only (APExBIO). This small molecule binds human MCL1 with a KD of 0.19 nM and exhibits a Ki below 1.2 nM. S63845 disrupts the interaction of MCL1 with pro-apoptotic BAX and BAK, activating mitochondrial apoptosis in cancer cells dependent on MCL1 for survival. In preclinical models, S63845 achieves sub-micromolar IC50s in hematological tumor cell lines and induces complete remission in mouse xenograft models with low toxicity. The compound is insoluble in water but dissolves efficiently in DMSO or methanol.

Biological Rationale

Myeloid cell leukemia 1 (MCL1) is a BCL-2 family protein that inhibits apoptosis by sequestering pro-apoptotic factors, such as BAK and BAX, at the mitochondrial outer membrane (Cell Death & Differentiation, 2026). MCL1 overexpression is a hallmark of many hematological malignancies, including multiple myeloma and lymphomas, where it confers resistance to cytotoxic therapies. The selective inhibition of MCL1 is therefore a strategic approach to sensitize cancer cells to apoptosis, particularly in tumors that evade cell death via upregulated anti-apoptotic machinery. S63845 was developed to address this target with high specificity and potency (product information).

Mechanism of Action of S63845 MCL1 inhibitor

S63845 is a BH3-mimetic that selectively binds to the BH3-binding groove of MCL1. This interaction prevents MCL1 from sequestering BAK and BAX, thereby enabling the activation of the mitochondrial apoptotic pathway. The release of BAK/BAX leads to mitochondrial outer membrane permeabilization (MOMP), cytochrome c release, and subsequent caspase activation resulting in apoptotic cell death (Cell Death & Differentiation). In MCL1-dependent cells, this pathway activation is rapid and robust, with hallmarks such as phosphatidylserine exposure and PARP cleavage observed within 24–48 hours of S63845 treatment (APExBIO).

Evidence & Benchmarks

• S63845 binds recombinant human MCL1 with a dissociation constant (KD) of 0.19 nM, confirming its high affinity (product specification).
• The inhibitor displays a Ki below 1.2 nM, demonstrating strong selectivity over other BCL-2 family members (product specification).
• In vitro, S63845 induces apoptosis in multiple myeloma and lymphoma cell lines with IC50 values < 0.1 μM after 48 hours at 37°C (APExBIO).
• In vivo, intravenous administration in immunocompromised mice bearing human myeloma xenografts leads to dose-dependent tumor growth inhibition and frequent complete remissions, with minimal toxicity in normal tissues (product information).
• Disruption of MCL1-BAK/BAX complexes by S63845 results in rapid cytochrome c release and caspase activation, as confirmed in mechanistic studies (Cell Death & Differentiation).

For a detailed comparison of S63845’s selectivity and applications, see S63845: A Selective MCL1 Inhibitor Empowering Apoptosis Research, which focuses on combinatorial strategies and resistance mechanisms. This article expands on precise workflow integration and new mechanistic evidence.

Additionally, Beyond Resistance: S63845 as a Precision MCL1 Inhibitor explores translational guidance and post-chemotherapy resistance, whereas our focus here includes protocol parameters and practical experimental design.

Applications, Limits & Misconceptions

S63845 is widely used as a research tool to dissect mitochondrial apoptotic signaling and evaluate the therapeutic potential of MCL1 inhibition in hematological malignancies. Its high selectivity allows for precise interrogation of BCL-2 family dependencies in cell death assays. However, its use is strictly limited to preclinical research settings, and it has not been approved for diagnostic or clinical applications (APExBIO).

Common Pitfalls or Misconceptions

• S63845 is not effective in cancer cells lacking MCL1 dependency; resistance may occur if BCL-2 or BCL-XL is upregulated (Redefining MCL1 Inhibition).
• The compound is intended for in vitro and animal model research only; it is not suitable for human therapeutic use (APExBIO).
• Stock solutions must be freshly prepared in DMSO and used promptly to avoid degradation (product information).
• S63845 is insoluble in aqueous buffers, which limits certain assay designs (product information).
• Non-specific toxicity may arise if excessive concentrations or prolonged exposure times are used outside recommended parameters.

Workflow Integration & Parameters

• Stock solution preparation: Dissolve S63845 (SKU A8737) in DMSO at ≥41.45 mg/mL or methanol at ≥20 mg/mL, as per the product guidelines.
• Storage: Store stock solutions at -20°C for several months; avoid repeated freeze-thaw cycles.
• Working solution: Dilute freshly into culture medium immediately prior to use; avoid prolonged exposure to light and room temperature.
• Treatment concentration: Typical experimental concentrations are 1–10 μM for 24–48 hours at 37°C, depending on cell line sensitivity.
• Assay compatibility: Suitable for apoptosis, cytotoxicity, and mitochondrial membrane potential assays in MCL1-dependent hematological cancer models.

For reproducibility tips and troubleshooting, S63845 (SKU A8737): Reliable MCL1 Inhibition for Apoptosis Assays offers a detailed protocol overview, while this article highlights mechanistic rationale and key application boundaries.

Conclusion & Outlook

S63845 is a best-in-class research tool for the selective inhibition of MCL1, enabling researchers to probe BAX/BAK-dependent apoptosis and overcome resistance mechanisms in hematological cancer models (Cell Death & Differentiation). Preclinical benchmarks demonstrate consistent nanomolar potency and minimal off-target toxicity. As mechanistic understanding of MCL1 in apoptosis deepens, S63845 and its workflow integration protocols will remain central to translational cancer research. Future research will refine its use in combination strategies and in mapping BCL-2 family dependencies, as evidenced by ongoing studies and the product's expanding adoption (APExBIO).